Chen Xiu-Li, Li Man, Zhang Xiao-Lan
Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, No. 215 Heping West Road, Shijiazhuang 050000, China.
Department of Epidemiology, School of Public Health, Hebei Medical University, Shijiazhuang, Hebei 050017, China.
Biomed Res Int. 2013;2013:672614. doi: 10.1155/2013/672614. Epub 2013 Nov 19.
A number of nucleoside analogues such as lamivudine (LAM), actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology, and enhance the rate of hepatitis B e antigen (HBeAg) clearance. The responses to LAM therapy involve HBeAg clearance and HBV DNA conversion of negative. However, the associations between HBV genotype B/C and response to LAM therapy remain ambiguous. The aim of this meta-analysis is to determine more precise estimations of the relationship. All the publications on the associations between HBV genotype B/C and response to LAM (HBeAg clearance and HBV DNA conversion of negative) through June 2013 were collected. Relative risk (RR) with 95% confidence intervals (95% CI) was calculated in fixed or random model, I² was calculated to examine heterogeneity, and funnel plots were plotted to examine small study effects with Stata 11 software. Overall, for HBeAg clearance and genotype B/C, the RR (95% CI) was 1.27 (0.94-1.71), while for HBV DNA conversion of negative and genotype B/C, the RR (95% CI) was 1.07 (0.98-1.17). HBV genotype B/C shows no significance associations with response to lamivudine therapy (HBeAg clearance and HBV DNA conversion of negative).
一些核苷类似物，如拉米夫定（LAM），实际上用于治疗慢性乙型肝炎，可抑制乙肝病毒（HBV）DNA复制，改善转氨酶水平和肝脏组织学，并提高乙肝e抗原（HBeAg）清除率。拉米夫定治疗的反应包括HBeAg清除和HBV DNA转阴。然而，HBV B/C基因型与拉米夫定治疗反应之间的关联仍不明确。本荟萃分析的目的是更精确地确定这种关系。收集了截至2013年6月所有关于HBV B/C基因型与拉米夫定治疗反应（HBeAg清除和HBV DNA转阴）之间关联的出版物。使用固定或随机模型计算相对风险（RR）及95%置信区间（95%CI），计算I²以检验异质性，并使用Stata 11软件绘制漏斗图以检验小研究效应。总体而言，对于HBeAg清除和B/C基因型，RR（95%CI）为1.27（0.94 - 1.71），而对于HBV DNA转阴和B/C基因型，RR（95%CI）为1.07（0.98 - 1.17）。HBV B/C基因型与拉米夫定治疗反应（HBeAg清除和HBV DNA转阴）无显著关联。
